Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world discontinuation of cBTKi-based treatments in patients with CLL/SLL in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

ZXZhaolin XuDalhousie UniversityPAPaolo AbadaEli Lilly (United States)

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high discontinuation rates of cBTKi in chronic lymphocytic leukemia, suggesting a need for better treatment options.

Key Points

  • Analyze the discontinuation rates of cBTKi-based treatments among patients with chronic lymphocytic leukemia in the US.
  • Retrospective observational study using a nationwide electronic health record database.
  • Selected adult patients diagnosed with chronic lymphocytic leukemia who initiated first cBTKi treatment.
  • Estimated time to treatment discontinuation and associated factors.
  • Approximately one-third of patients discontinued treatment by the end of the first year.
  • Median time to discontinuation was 35.4 months for first-line monotherapy.
  • High rates of early discontinuation raise questions about treatment tolerability.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1bfhttps://doi.org/10.1182/blood-2025-8030
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States2025
  2. 2Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  3. 3Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  4. 4Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.2026
  5. 5Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025